• 3-Aminobenzamide (PARP-IN-1): Precision PARP Inhibition for

  2026-05-25

  This thought-leadership article explores the mechanistic and translational significance of 3-Aminobenzamide (PARP-IN-1) in dissecting poly (ADP-ribose) polymerase function. Bridging cardiovascular, metabolic, and emerging antiviral models, it delivers protocol guidance, strategic positioning, and future outlook for translational researchers.

• EZ Cap Cy5 Firefly Luciferase mRNA: Dual-Mode mRNA Tracking

  2026-05-24

  Explore how EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) empowers advanced mRNA delivery and dual-mode imaging in translational research. This article provides new insights into intracellular tracking and stability, grounded in recent mucosal delivery breakthroughs.

• a-MSH, amide: Protocol Optimization for Pigmentation Researc

  2026-05-23

  Leverage a-MSH, amide for robust, reproducible assays in pigmentation regulation and anti-inflammatory peptide research. Explore protocol enhancements, troubleshooting strategies, and insights from the latest anti-melanogenic reference study for actionable improvements in your experimental workflows.

• TCF25 Orchestrates Lysosomal Cell Fate Under Glucose Starvat

  2026-05-22

  Ren et al. identify TCF25 as a crucial transcription factor that senses glucose deprivation and modulates lysosomal acidification, autophagy, and cell death. This work provides mechanistic insight into metabolic adaptation and offers new targets for diseases involving nutrient stress, including potential implications for cancer and ischemic injury.

• EPO-BM-MSCs Enhance Mitochondrial Transfer to Alleviate Asth

  2026-05-22

  This study demonstrates that erythropoietin-modified bone marrow mesenchymal stem cells (EPO-BM-MSCs) alleviate asthma inflammation by enhancing mitochondrial activation and transfer to airway epithelial cells, primarily via upregulation of HO-1. These findings outline a novel mechanistic pathway for cellular repair in asthma and suggest new avenues for targeted therapies.

• Ruxolitinib (INCB018424): Optimizing JAK-STAT Pathway Inhibi

  2026-05-21

  Harness Ruxolitinib’s selective JAK1/2 inhibition for robust myeloproliferative disorder and oncogenic JAK2 fusion protein research. This guide delivers actionable workflow enhancements, troubleshooting strategies, and translational insights, bridging foundational studies with optimized immune profiling in the lab.

• IR-1061 (SKU C8242): Deep Tissue Imaging Reliability for Lab

  2026-05-21

  This article delivers evidence-based guidance on deploying IR-1061 (SKU C8242), a near infrared fluorescent dye from APExBIO, for high-resolution in vivo and deep tissue imaging. Scenario-driven analysis addresses practical workflow challenges, protocol optimization, and product selection, enabling researchers to achieve reproducible and sensitive results in fluorescence-based assays.

• Patient-Derived Gastric Cancer Assembloids Advance Tumor Mod

  2026-05-20

  This study introduces a robust assembloid system integrating matched tumor organoids and autologous stromal cell subpopulations from gastric cancer patients. The model enhances physiological relevance for drug response studies, providing new insights into tumor-stroma interactions and resistance mechanisms.

• JAK Inhibitors Block Sensory Neuron Activation in RA: Mechan

  2026-05-20

  This study demonstrates that Janus kinase inhibitors (JAKi) directly block sensory neuron activation triggered by rheumatoid arthritis synovial fluid, offering mechanistic insights into their superior pain-relieving effects. Using human iPSC-derived neurons and advanced protein analysis, the findings clarify the cellular pathways underlying chronic pain in RA and suggest new avenues for targeted analgesic therapy.

• Angiotensin 1/2 (2-7): Shaping Next-Gen Cardiovascular & Vir

  2026-05-19

  This thought-leadership article explores how Angiotensin 1/2 (2-7), a high-purity vasoconstrictor peptide from APExBIO, enables translational researchers to dissect the renin-angiotensin system with unprecedented specificity. Drawing on recent peer-reviewed studies, it illuminates mechanistic insights, experimental protocols, and the evolving intersection between cardiovascular and infectious disease research—charting a strategic path for modeling hypertension, aldosterone dynamics, and SARS-CoV-2 spike-receptor interactions.

• Phosbind Biotin LC: Practical Guide for Western Blot Phospho

  2026-05-19

  Phosbind Biotin LC addresses the challenge of sequence-independent detection of phosphorylated proteins on PVDF membranes, offering an alternative to phospho-specific antibodies in Western Blot assays. It is unsuitable for aqueous-only protocols and long-term storage in solution due to critical solubility and stability requirements.

• ML-7 Hydrochloride: Precision Myosin Light Chain Kinase Inhi

  2026-05-18

  ML-7 hydrochloride empowers cardiovascular and vascular researchers to precisely interrogate MLCK-mediated pathways, offering robust inhibition and reproducibility for ischemia/reperfusion injury and endothelial dysfunction models. This article translates cutting-edge findings into actionable workflows, troubleshooting strategies, and comparative insights for maximizing experimental success.

• Estradiol, ER Stress, and CD4+ T Cell Recovery After Hemorrh

  2026-05-18

  This study investigates how 17β-estradiol (E2) restores immune function after hemorrhagic shock by inhibiting endoplasmic reticulum stress (ERS) in splenic CD4+ T cells. It demonstrates that E2’s beneficial effects depend specifically on ERα and GPR30, not ERβ, and are abolished by ER antagonists, establishing a mechanistic basis for immune modulation via estrogen signaling.

• AM251 as a CB1 Receptor Antagonist: Protocols and Pitfalls

  2026-05-17

  AM251 is a high-affinity CB1 receptor antagonist enabling precise dissection of endocannabinoid signaling in neuropharmacology and metabolic research. This guide delivers stepwise protocols, advanced troubleshooting, and workflow optimization tips—bridging bench experimentation with translational outcomes.

• Tariquidar (XR9576): Mechanotransduction, P-gp, and Drug Res

  2026-05-16

  Explore how Tariquidar (XR9576) enables rigorous mechanotransduction studies and advanced drug resistance research. This article uniquely reveals the interface between tumor mechanics, P-gp upregulation, and transporter inhibition—bridging molecular function with practical assay design.

450 records 17/30 page Previous Next First page 上5页 1617181920 下5页 Last page